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ABSTRACT
Background
Somatic mutations in the kinase domain of the epidermal growth factor receptor tyrosine
kinase gene EGFR are common in lung adenocarcinoma. The presence of mutations correlates
with tumor sensitivity to the EGFR inhibitors erlotinib and gefitinib, but the transforming
potential of specific mutations and their relationship to drug sensitivity have not been
described.
Methods and Findings
Here, we demonstrate that EGFR active site mutants are oncogenic. Mutant EGFR can
transform both fibroblasts and lung epithelial cells in the absence of exogenous epidermal
growth factor, as evidenced by anchorage-independent growth, focus formation, and tumor
formation in immunocompromised mice. Transformation is associated with constitutive
autophosphorylation of EGFR, Shc phosphorylation, and STAT pathway activation. Whereas
transformation by most EGFR mutants confers on cells sensitivity to erlotinib and gefitinib,
transformation by an exon 20 insertion makes cells resistant to these inhibitors but more
sensitive to the irreversible inhibitor CL-387,785.
Conclusion
Oncogenic transformation of cells by different EGFR mutants causes differential sensitivity to
gefitinib and erlotinib. Treatment of lung cancers harboring EGFR exon 20 insertions may
therefore require the development of alternative kinase inhibition strategies.
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The human epidermal growth factor receptor gene
product (EGFR), a member of the ErbB family of receptor
tyrosine kinases, is an integral component of signaling in
epithelial cell proliferation. Stimulation of the receptor with
EGF or other cognate ligands induces receptor dimerization
and autophosphorylation, providing docking sites for SH2-
containing adaptor proteins that mediate the activation of
intracellular signaling pathways [1–3].
Consistent with a role in proliferative signaling, the
oncogenic potential of EGFR variants with deletions in the
extracellular domain, including the v-erbB oncogene of avian
erythroblastosis virus and the vIII mutant found in human
cancers, transforms vertebrate cells in the absence of
exogenous EGF [4–7]. In contrast, overexpression of the
wild-type EGFR gene can transform NIH-3T3 cells only upon
EGF addition [8]. Kinase activity is required for ligand-
independent transformation by both types of EGFR extra-
cellular domain deletion mutant [9,10].
A series of novel EGFR kinase domain mutations observed
in human lung adenocarcinomas has recently been described
[11–16]. These mutations arise in four exons: substitutions for
G719 in the nucleotide-binding loop of exon 18, in-frame
deletions within exon 19, in-frame insertions within exon 20,
and substitutions for L858 or L861 in the activation loop in
exon 21. Tumors from patients with clinical responses to the
EGFR inhibitors geﬁtinib or erlotinib have been shown to
contain EGFR deletion mutations or substitution mutations
[11,12,13,15], but no exon 20 insertion mutations have been
reported in this group of clinical responders. Although exon
20 mutations were not widely reported at ﬁrst, recently ﬁve
large-scale studies that sequenced EGFR exons 18 through 21
reported a total of 18 exon 20 insertions out of 350 EGFR
mutations identiﬁed in 1,108 non-small-cell lung cancers [14–
18]. Patients who responded to geﬁtinib and subsequently
relapsed were found to have T790M secondary mutations,
also in exon 20 [19,20].
Although geﬁtinib treatment and small interfering RNA
experiments suggest that cells expressing mutant EGFR are
dependent on EGFR function for survival [11,21,22], the
direct transforming potential of the mutations observed in
lung adenocarcinoma has not been described. Here, we assess
the ability of these EGFR kinase domain mutations to
constitutively activate EGFR signaling and contribute to
tumorigenesis in model cell culture systems.
Methods
Cell Culture
NIH-3T3 cells obtained from ATCC (Manassas, Virginia,
United States) were maintained in DMEM (Cellgro/Mediatech,
Herndon, Virginia, United States) supplemented with 10%
calf serum (Gibco/Invitrogen, Carlsbad, California, United
States) and penicillin/streptomycin (Gibco/Invitrogen). NCI-
H3255 cells were maintained in ACL-4 media as previously
described [11]. Unless otherwise noted, cells were placed in
media containing 0.5% calf serum 24 h prior to EGF
(Biosource, Camarillo, California, United States) stimulation.
hTBE cells expressing SV40 small T and large T antigens and
the human telomerase catalytic subunit hTERT were main-
tained in serum-free, deﬁned medium as described [23].
Neutralizing antibodies were added 3 h prior to EGF
stimulation at the following concentrations: 12 lg/ml anti-
EGF (R&D Systems, Minneapolis, Minnesota, United States;
#MAB636), 12 lg/ml anti-TGFa (R&D Systems; #AF-239-NA),
and 12 lg/ml anti-EGFR (Upstate, Waltham, Massachusetts,
United States; #05–101). Geﬁtinib and erlotinib were pur-
chased from WuXi Pharmatech (Shanghai, China) and diluted
in DMSO to the indicated concentrations. CL-387,785 was
purchased from Calbiochem (San Diego, California, United
States) and diluted in DMSO to the indicated concentrations.
Expression Constructs
EGFR was ampliﬁed from a cDNA template with the PCR
primers 59-GATGATATCATGCGACCCTCCGGGAC-39 and
59-ATCGATATCTCATGCTCCAATAAATTC-39,d i g e s t e d
with EcoRV, and inserted into the SnaB1 site of pBabe-Puro.
Point mutations, insertions, and deletions were made using
the Quick-Change Mutagenesis XL kit (Stratagene, La Jolla,
California, United States) with the following oligonucleotide
primers: 59-AAGATCACAGATTTTGGGAGGGCCAAAC-
TGCTGGGTG-39 and 59-CACCCAGCAGTTTGGCCCTCCC-
AAAATCTGTGATCTT-39 for L858R; 59-AAGATCAAAGTG-
CTGAGCTCCGGTGCGTTCG-39 and 59-CGAACGCACCG-
GAGCTCAGCACTTTGATCTT-39 for G719S; 59-GGTGCA-
CCGCGCCCTGGCAGCCA-39 and 59-TGGCTG-
CCAGGGCGCGGTGCACC-39 for D837A; 59-GTCGCTAT-
CAAGGAACCAACATCTCCGAAA-39 and 59-TTTCGGAGA-
TGTTGGTTCCTTGATAGCGAC-39 for L747_E749del,
A750P; 59-GGCCAGCGTGGACAACCCCGGCAACCCC-
CACGT-39 and 59-ACGTGGGGGTTGCCGGGGTTGTC-
CACGCTGGCC-39 for D770_N771insNPG. All constructs
were fully sequenced.
Transfection and Infection
Replication incompetent retroviruses were produced from
pBabe-Puro-based vectors either by cotransfection of 293T
cells with pCL-Ampho (Imgenex, San Diego, California,
United States) or by transfection into the Phoenix 293T
packaging cell line (Orbigen, San Diego, California, United
States) using Lipofectamine 2000 (Invitrogen). Cells were
infected with these retroviruses in the presence of polybrene.
Two days after infection, puromycin (2 lg/ml for NIH-3T3s or
0.5 lg/ml for hTBE cells; Sigma, St. Louis, Missouri, United
States) was added and pooled stable cell lines were selected,
from which clonal cell lines were derived.
Soft Agar Anchorage-Independent Growth Assay
EGFR-expressing NIH-3T3 cells were suspended in a top
layer of DMEM containing 10% calf serum and 0.4% Select
agar (Gibco/Invitrogen) and plated on a bottom layer of
DMEM containing 10% calf serum and 0.5% Select agar. EGF,
geﬁtinib, or erlotinib was added as described to the top agar.
NIH-3T3 colonies were counted in triplicate wells from ten
ﬁelds photographed with a 103 objective. Growth of hTBE
cells in soft agar was determined by plating 1 3 10
5 cells in
triplicate in 0.4% Noble agar. Colonies of hTBE cells were
counted microscopically 6–8 wk after plating with the
MultiImage imaging counter (Alpha Innotech, San Leandro,
California, United States).
Focus Formation Assay
NIH-3T3 cells infected with EGFR retrovirus diluted 1:1,
1:10, or 1:100 were split 2 d after infection into 10-cm plates
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assay were maintained without passage as a monolayer in the
absence of puromycin for 3 wk, after which foci were stained
with crystal violet (Accustain; Sigma) and scored. Numbers of
foci were multiplied by the viral dilution factor and
normalized to the relative number of infectious units in each
viral stock, as determined by a WST assay (Roche, Basel,
Switzerland) on cells after 3 d of puromycin selection.
Nude Mouse Injection
In this assay, 2310
6 cells were injected subcutaneously into
immunocompromised mice, three injections per animal, as
described [24]. Tumors were counted and tumor diameter
was measured after 5 wk. Standard error of the mean is
indicated.
Immunoblotting
Cells were lysed in a buffer containing 50 mM Tris-HCl (pH
7.4), 150 mM NaCl, 2.5 mM EDTA, 1% Triton X-100, and
0.25% IPEGAL. Protease inhibitors (Roche) and phosphatase
inhibitors (Calbiochem) were added prior to use. Samples
were normalized for total protein content unless otherwise
indicated. Lysates were boiled in sample buffer, separated by
SDS-PAGE on 8% or 10% polyacrylamide gels, transferred to
nitrocellulose, and probed as described. Antibodies used for
immunoblotting were: anti-EGFR (#2232, Cell Signaling
Technologies), anti-phospho-EGFR Y1173 (#05–483, Upstate),
anti-phospho-EGFR Y1068 (#2234, Cell Signaling Technolo-
gies), anti-phospho-EGFR Y845 (Cell Signaling Technologies,
Beverly, Massachusetts, United States; #2231), anti-phospho-
EGFR Y1045 (Cell Signaling Technologies; #2237), anti-actin
(Santa Cruz Biotechnology, Santa Cruz, California, United
States; #sc-1615), anti-Shc (Upstate; #06–203), anti-phospho-
Shc Y317 (Upstate; #05–668), anti-Stat3 (Cell Signaling
Technologies; #9132), and anti-phospho-Stat3 Y705 (Cell
Signaling Technologies; #9131), anti-phospho-Akt S473 (Cell
Signaling Technologies; #9271), and anti-Akt (Cell Signaling
Technologies; #9272).
Figure 1. Mammalian Cells Expressing the Lung Cancer-Derived Mutant
EGFR Grow in an Anchorage-Independent Manner
(A) NIH-3T3 cells infected with retroviruses encoding the indicated wild-
type or mutant EGFR were selected in the presence of 2.5 lg /ml
puromycin for 4 d. In the top photomicrographs, 1 3 10
5 cells were
suspended in soft agar for a colony formation assay and photographed
after 3 wk incubation at 37 8C. Expression of lung cancer-derived
missense EGFR mutants, but not wild-type or kinase-inactive D837A
EGFR, induces colony formation in soft agar. In the bottom photomicro-
graphs, samples were identical, but 20 ng/ml EGF was added to the top
agar. Representative photomicrographs are shown.
(B) Anti-EGFR immunoblot analysis of pooled stable NIH-3T3 cells
infected as described in (A). All EGFR constructs are expressed at similar
levels. pBp, pBabe-Puro vector; wt, wild-type EGFR.
(C) Lysates from 4310
4 cells from the human lung adenocarcinoma cell
line H3255, harboring the L858R mutation in EGFR, or the wild-type or
L858R EGFR-overexpressing NIH-3T3 cells, were immunoblotted for total
EGFR levels. Although total protein levels per cell are lower for the H3255
than the NIH-3T3 cells, EGFR expression levels are slightly higher in the
H3255s.
(D) NIH-3T3 cells infected with retroviruses encoding the mutant EGFR
were selected in the presence of 2 lg/ml puromycin for 9 d. Selected
cells (1 310
5) were suspended in soft agar for a colony formation assay
and photographed after 3 wk incubation at 37 8C. Expression of the
deletion and insertion EGFR mutants induced formation of colonies in
soft agar with higher efficiency than expression of L858R. Representative
photos are shown. Polyoma mT, NIH-3T3 cells infected with positive
control pBabe-Puro retrovirus encoding the polyoma middle T antigen.
(E) hTBE cells expressing the SV40 early region and hTERT were infected
with control virus pBabe-Puro (pBp) or with viruses encoding the
indicated EGFR alleles. Cells were plated in 0.4% Noble agar, and colonies
were counted with an automated imager at 6 wk. Mean 6 standard
deviation is shown for three independent determinations. Control cells
(pBp) formed many microscopic colonies, but colonies formed by cells
expressing EGFR mutants were more numerous and larger. del,
L747_E749del A750P mutated EGFR; ins, D770_N771insNPG mutated
EGFR; pBp, pBabe-Puro vector; RasV12, V12 H-Ras; wt, wild-type EGFR.
(F) Anti-EGFR immunoblot analysis of hTBE cells infected as described in
(E). All EGFR constructs were expressed at similar levels. pBp, pBabe-Puro
vector; wt, wild-type EGFR.
DOI: 10.1371/journal.pmed.0020313.g001
Table 1. NIH-3T3 Cells Expressing the Lung Cancer-Derived
Mutant EGFR Display Loss of Contact Inhibition
Retrovirus Normalized Foci
pBabe-Puro 0
Wild-type EGFR 0
L858R 1,280
G719S 975
D837A 0
DOI: 10.1371/journal.pmed.0020313.t001
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Cells were lysed as described above. Anti-EGFR conjugated
beads (Santa Cruz Biotechnology; #sc-120AC) were used for
immunoprecipitation. Beads (25 ll) were incubated with
fresh lysate in 300 ll of lysis buffer for 1 h, washed twice with
lysis buffer, eluted in 1% SDS at room temperature for 20
min, and boiled in sample buffer.
Luciferase Assay
The STAT3 (signal transducer and activator of tran-
scription 3) reporter m67 pTATA TK-luc [25] was kindly
provided by J. Bromberg, and the Renilla luciferase reporter
phRL tk-luc was purchased from Promega (Madison, Wiscon-
sin, United States). NIH-3T3 cells, infected with EGFR or
control retroviruses, were plated on 24-well plates and
transfected with 2 lg of m67-luc and 0.2 lg phRL tk-luc with
Lipofectamine 2000 (Invitrogen). After 48 h, cells were lysed
and luminescence was measured using the dual-luciferase
reagents from Promega, according to the manufacturer’s
instructions, using a Luminoskan Ascent luminometer (Ther-
moLab Systems, Helsinki, Finland). STAT3-dependent luci-
ferase production was normalized to chemiluminescence
values from the control Renilla luciferase.
Results
Expression of Mutant EGFR Induces Oncogenic
Transformation
To assess the oncogenic potential of EGFR kinase domain
mutants, tumor-derived mutations were introduced into the
wild-type human EGFR cDNA by site-directed mutagenesis.
The resulting wild-type and mutant EGFR cDNAs were then
cloned into the pBabe-Puro retroviral vector and transferred
into NIH-3T3 cells by retroviral infection. We initially
examined two representative substitution mutations: G719S,
observed in exon 18, and L858R, observed in exon 21 (Figure
1). The L858R and G719S mutants were able to transform
NIH-3T3 cells to anchorage independence in the absence of
exogenous EGF, as assayed by colony formation in soft agar
(Figure 1A, top photographs). In contrast, as previously
described [8], wild-type EGFR transformed only upon EGF
addition (Figure 1A, bottom photographs). The kinase-dead
D837A mutant [9], included as a negative control, failed to
induce colony formation in the presence or absence of EGF.
EGFR expression levels were approximately equal for each
pooled stably-transfected cell population (Figure 1B). Clonal
cell lines derived from the pooled stably-transfected cells
expressing the mutant EGFR exhibited profound morpho-
logical alterations characterized by a fusiform, refractile
phenotype (unpublished data). Levels of L858R EGFR
expression necessary to achieve transformation in this model
cell culture system were no higher than expression levels
observed in the human lung adenocarcinoma cell line H3255
bearing the L858R mutation (Figure 1C).
Transformation of NIH-3T3 cells by L858R or G719S EGFR
Table 2. Clonal NIH-3T3 Cell Lines Expressing the Lung Cancer-
Derived Mutant EGFR Form Tumors in Immunocompromised
Mice
Retrovirus Number of Tumors Average Tumor Diameter, mm
pBabe-Puro 0/3 0
Wild-type EGFR 0/3 0
L858R 6/6 12 6 0.8
a
G719S 4/4 7 6 0.9
a
D837A 0/3 0
aStandard error of the mean
DOI: 10.1371/journal.pmed.0020313.t002
Figure 2. Ligand-Independent Activation of the Mutant EGFR
(A) Cells expressing the wild-type or mutant EGFR were lysed and
immunoblotted with antibodies to total EGFR or antibodies that
recognize specific phosphorylation sites in the EGFR C-terminal tail as
labeled. All four mutant EGFR proteins, representative of the four classes
of EGFR mutations observed in lung adenocarcinoma tumor DNA,
exhibited constitutive phosphorylation on the indicated C-terminal
autophosphorylation sites. Note that the nomenclature for the anti-
phospho-EGFR antibodies reflects elimination of the 24-amino acid
signal peptide. Due to difficulties in isolating clonal cell lines with the
same levels of mutant EGFR expression, G719S is expressed at higher
levels and D770_N771ins NPG at lower levels than the other mutant
EGFR. del, L747_E749del A750P; ins, D770_N771insNPG; pBp, pBabe-Puro
vector control; wt, wild-type EGFR.
(B) Cells expressing the wild-type or L858R EGFR were placed in media
containing 0.5% CS for 24 h. A combination of three neutralizing
antibodies (anti-EGF, anti-TGFa, and anti-EGFR) was added 3 h prior to
EGF stimulation and lysis. Upper row of blots show the anti-phospho-
EGFR Y1068 immunoblots. The lower row shows anti-EGFR immunoblots.
No inhibition of L858R EGFR autophosphorylation was observed upon
treatment with a combination of three neutralizing antibodies (‘‘neutr
Ab’’) sufficient to prevent EGF stimulation of autophosphorylation of the
wild-type EGFR.
DOI: 10.1371/journal.pmed.0020313.g002
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Oncogenic Transformation by Mutant EGFRwas further assessed in two independent assays. Expression of
the EGFR point mutants in NIH-3T3 cells caused loss of
contact inhibition, resulting in focus formation on an
unselected monolayer, whereas the wild-type and D837A
kinase-inactive controls did not (Table 1). In addition,
injection of clonal, transformed NIH-3T3 ﬁbroblasts express-
ing L858R and G719S EGFR into immunocompromised mice
led to the formation of tumors (Table 2). No tumor formation
was observed upon injection of cells infected with vector,
wild-type, and kinase-dead controls.
Representative exon 19 deletion and exon 20 insertion
mutations of EGFR were then assessed for transforming
activity. Mutants L747_E749del, A750P [11] and
D770_N771insNPG (K. Naoki and M. M., unpublished data)
were introduced into NIH-3T3 cells by retrovirus-mediated
gene transfer as described above. Cells expressing the EGFR
deletion and insertion mutants formed colonies in soft agar
with a higher efﬁciency than that of cells expressing the
missense mutants, comparable to the colony formation
efﬁciency of cells expressing polyoma middle T antigen
(Figure 1D). Expression of the deletion mutant was compa-
rable to that of L858R EGFR, whereas expression of the
Figure 3. Shc and STAT3 Signaling Pathways Are Constitutively Activated in Cells Expressing the Mutant EGFR
(A) Cells expressing the wild-type or L858R mutant EGFR were placed in 0.5% calf serum for 24 h and left unstimulated or stimulated with 20 ng/ml EGF
(‘‘þEGF’’) for 8 min. EGFR was immunoprecipitated from 200 lg of cell lysate, and eluted immune complexes were separated by SDS-PAGE and
immunoblotted with anti-Shc. Shc constitutively coimmunoprecipitates with the L858R EGFR but not the wild-type EGFR. IP, immunoprecipitation; NL,
no-lysate control immunoprecipitation.
(B) Anti-phospho-Shc immunoblots (upper row of blots) and anti-Shc immunoblots (lower row) of whole cell lysates from the experiment in (A). All
three Shc isoforms are constitutively phosphorylated in cells expressing the L858R EGFR.
(C) Immunoblots of whole cell lysates with anti-phospho-STAT3 Y705 (upper row), total STAT3 (middle row), or actin as a loading control (lower row).
STAT3 is constitutively phosphorylated in cells expressing any of the four mutant EGFR proteins, representative of the four classes of EGFR mutations
observed in lung adenocarcinoma tumor DNA. del, L747_E749del A750P; ins, D770_N771insNPG; pBp, pBabe-Puro vector control; wt, wild-type EGFR.
(D) M67 STAT3 luciferase reporter assay. NIH-3T3 cells expressing the indicated EGFR were transfected with a STAT-dependent reporter (m67-firefly
luciferase) [25] and a control reporter expressing Renilla luciferase. STAT-dependent luciferase production was measured after 48 h and normalizedt o
Renilla luciferase. The normalized luciferase values were divided by the values for cells expressing the wild-type EGFR to produce relative luciferase
units. NIH-3T3 expressing mutant forms of EGFR exhibited elevated levels of STAT-dependent transcriptional activity relative to wild-type. ins,
D770_N771insNPG EGFR; wt, wild-type EGFR.
(E) Immunoblots of whole cell lysates with anti-phospho-Akt S473 (upper row), total Akt (middle row), or actin as a loading control (lower row). Akt is
constitutively phosphorylated in cells expressing mutant EGFR. del, L747_E749del A750P; ins, D770_N771insNPG; wt, wild-type EGFR.
DOI: 10.1371/journal.pmed.0020313.g003
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Oncogenic Transformation by Mutant EGFRinsertion mutant was lower, as reﬂected in the EGFR
expression levels of the clonal cell lines (Figure 2A and
unpublished data). Cells expressing the L747_E749del A750P
and D770_N771insNPG EGFR mutants also exhibited a
greater degree of loss of contact inhibition than was observed
in cells expressing the L858R or G719S EGFR mutants in a
primary focus formation assay (unpublished data).
To determine the ability of mutant EGFR to transform a
more physiologically relevant cell type, retroviruses express-
ing the L858R and G719S mutant forms of EGFR were
Figure 4. Sensitivity of Cell Transformation Induced by Expression of Mutant EGFR Characterized by Missense Mutation or Exon 19 Deletion, but not
Exon 20 Insertion, to Gefitinib and Erlotinib
(A) Anchorage-independent growth of clonal NIH-3T3 cells transformed with mutant EGFR or EGF-stimulated wild-type EGFR treated with the indicated
concentrations of erlotinib immediately prior to suspension in soft agar. Transformation induced by expression of L858R, G719S, and L747_E749del
A750P EGFR, but not EGF-stimulated wild-type EGFR or D770_N771insNPG EGFR, was inhibited by 0.1 lM erlotinib. Representative photographs are
shown.
(B) Number of colonies formed in soft agar by clonal NIH-3T3 cells expressing L858R EGFR and D770_N771insNPG EGFR treated with the indicated
concentrations of gefitinib or erlotinib immediately prior to suspension in soft agar. Transformation by cells expressing the L858R EGFR was inhibited by
0.1 lM gefitinib or erlotinib, whereas transformation by cells expressing the insertion mutant was resistant to low concentrations of these inhibitors.
Colonies were quantitated by counting ten fields each of triplicate wells photographed with a 103objective; mean 6 standard deviation is shown. Ins,
D770_N771insNPG EGFR.
(C) Transformation induced by expression of D770_N771insNPG EGFR is inhibited 10-fold more efficiently by the irreversible EGFR inhibitor CL-387,785
[35]. Clonal NIH-3T3 cells expressing the insertion mutant were treated with the indicated concentrations of gefitinib, erlotinib, or CL-387,785
immediately prior to suspension in soft agar. This assay was not done in triplicate, but the results are representative of two independent experiments.
The number of colonies was normalized to maximum colony formation for each treatment, and sigmoidal dose response curves were fitted to the data
using Prism Graphpad software to determine IC50s.
DOI: 10.1371/journal.pmed.0020313.g004
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Oncogenic Transformation by Mutant EGFRintroduced into hTBE cells expressing the SV40 early region
T antigens and the human telomerase catalytic subunit
hTERT [23]. We previously showed that such cells are fully
transformed by the additional expression of oncogenic alleles
of H- or K-RAS [23]. Similarly, the expression of L858R and
G719S mutant EGFR genes conferred enhanced anchorage-
independent growth upon such hTBE cells, with colony
numbers approximately 15-fold above the background level
of microscopic colonies observed in hTBE cells expressing
wild-type EGFR or a control vector (Figure 1E). The
representative deletion and insertion mutants,
L747_E749del A750P and D770_N771insNPG, formed
colonies in soft agar with even greater efﬁciency, with the
caveat that the deletion mutant is expressed at higher levels
than the other mutants in this assay (Figure 1F). Similar to
hTBE cells expressing H-RAS V12, expression of these EGFR
mutants did not increase the rate of cell proliferation in
deﬁned medium (unpublished data).
Multiple tumor-derived mutants of EGFR therefore con-
tribute to oncogenic transformation as shown by three
different assays: anchorage-independent cell growth, focus
formation, and in vivo tumor formation.
Mutant EGFR Proteins Are Constitutively Active
To determine whether transformation by mutant EGFR is
associated with constitutive receptor activation in the
absence of exogenous EGF, tyrosine autophosphorylation in
the C-terminal tail of EGFR was examined by immunoblot-
ting of cell lysates. Constitutive tyrosine phosphorylation of
the mutant EGFR molecules was observed at several C-
terminal sites, including Y845, Y1068, and Y1173 (Figure 2A).
High-level phosphorylation of the insertion mutant at Y1045,
the docking site for the Cbl E3 ubiquitin ligase [26], is
Figure 5. Sensitivity of Mutant EGFR Autophosphorylation to EGFR Inhibitors Reflects Inhibition of Anchorage-Independent Growth
Cells expressing wild-type, L858R, or D770_N771insNPG EGFR were treated for 2 h with the indicated concentrations of gefitinib or CL-387,785. Cells
expressing the wild-type EGFR were then stimulated for 10 min with 7 ng/ml EGF, and all plates were lysed. Whole-cell lysates were immunoblotted for
phospho-EGFR Y1068 (upper row of blots), total EGFR (middle row), and actin as a loading control (lower row). Although compound concentrations
necessary for inhibition of autophosphorylation do not exactly correspond to inhibition of anchorage-independent growth, the relative sensitivity of
autophosphorylation of the wild-type and mutant EGFR to gefitinib or CL-387,785 mirrors the relative sensitivity of colony formation to these inhibitors.
DOI: 10.1371/journal.pmed.0020313.g005
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Oncogenic Transformation by Mutant EGFRcorrelated with decreased abundance of this protein (Figure
2A), but whether the differential protein levels are a result of
Cbl activity has not been conﬁrmed.
The constitutive increase in EGFR activity appears to be
ligand-independent, as a combination of neutralizing anti-
bodies against EGF, TGFa, and EGFR failed to inhibit
elevated basal levels of L858R autophosphorylation (Figure
2B). However, tyrosine phosphorylation on the EGFR
mutants could be further increased by EGF stimulation
(Figure 2B), suggesting that the mutant EGFRs exhibit both
ligand-independent and ligand-dependent activation, similar
to that observed upon EGF stimulation of the L858R mutant
H3255 lung adenocarcinoma cell line [21]. Ligand-independ-
ent activation of EGFR with lung cancer-derived kinase
domain mutations has not been observed by other groups
working with transient transfection systems [22,27]. We too
have failed to detect constitutive elevation of mutant
receptor autophosphorylation when transiently expressed in
NIH-3T3 and HeLa cells (unpublished data). The reason for
this phenotypic difference remains unclear.
Expression of Mutant EGFR Results in Activation of Shc,
STAT3, and Akt
We next asked whether constitutive activation of mutant
EGFR is associated with alterations in downstream signaling
pathways. Because Y1173, a docking site for the adaptor
protein Shc [28], is constitutively phosphorylated on mutant
EGFR (Figure 2A), we analyzed Shc-EGFR complex formation
in cells expressing wild-type and mutant EGFR. Coimmuno-
precipitation studies revealed a low level of constitutive Shc
binding to the L858R EGFR, further augmented by EGF
stimulation (Figure 3A), whereas Shc complexed with the
wild-type EGFR only upon EGF stimulation. Immunoblotting
of whole cell lysates with an antibody speciﬁc for tyrosine-
phosphorylated Shc revealed constitutive phosphorylation on
Shc in cells expressing the L858R EGFR, consistent with the
known phosphorylation of EGFR-bound Shc [29]; in contrast,
in cells expressing wild-type EGFR, Shc was phosphorylated
only in response to EGF stimulation (Figure 3B). Similar to
the situation with receptor autophosphorylation, constitutive
phosphorylation of Shc in mutant EGFR-expressing cells has
not been observed in transient expression systems [27].
Consistent with previous reports on L858R mutant EGFR
[22], STAT signaling pathways are constitutively activated in
the transformed NIH-3T3 cells. Immunoblotting with anti-
bodies speciﬁc for phosphorylated Y705, the tyrosine
responsible for STAT3 dimerization [30], revealed constitu-
tive phosphorylation in cells expressing the lung cancer-
derived mutant EGFR but not wild-type EGFR (Figure 3C).
Increased STAT3-dependent gene expression in cells ex-
pressing the mutant EGFRs was conﬁrmed in a reporter assay
(Figure 3D) using a STAT-dependent luciferase construct
[25].
Constitutive phosphorylation of mutant EGFR on Y1068
(see Figure 2A), the binding site for the phosphatidylinositol
3-kinase interacting protein Gab1 [31], indicated that signal-
ing pathways downstream of phosphatidylinositol 3-kinase
might be constitutively activated as well. One such pathway is
controlled by the serine/threonine kinase Akt, which is
involved in promotion of cell survival. Western blotting with
anti-phospho-Akt conﬁrmed that Akt is constitutively acti-
vated in cells expressing the mutant EGFR (Figure 3E). We
therefore conclude that at least a subset of physiological
EGFR signaling pathways is activated by stable expression of
mutant EGFR.
Transformation by the Exon 20 Insertion Mutant Is Not
Sensitive to Gefitinib or Erlotinib
Given the association between the presence of activating
EGFR mutations and clinical responses to geﬁtinib or
erlotinib in lung adenocarcinoma patients [11,12,13,15], we
assessed the ability of these EGFR inhibitors to inhibit
anchorage-independent growth of clonal NIH-3T3 cell lines
expressing wild-type or mutant EGFR. Consistent with the
increased sensitivity to geﬁtinib and erlotinib of patient
tumors harboring the missense mutations or exon 19
deletions, anchorage-independent growth of cells expressing
L858R, G719S, or L747_E749del A750P was inhibited by 100
nM erlotinib (Figure 4A and 4B) or geﬁtinib (Figure 4B and
unpublished data), although the G719S mutant may be
somewhat more resistant to geﬁtinib (Figure 4A and
unpublished data), consistent with other in vitro studies
[32]. In contrast, 1 lM erlotinib (Figure 4A) or geﬁtinib
(unpublished data) did not inhibit anchorage-independent
growth of EGF-treated cells overexpressing the wild-type
EGFR.
Transformation by the D770_N771insNPG EGFR mutant
was remarkably insensitive to geﬁtinib and erlotinib, as
inhibition of colony growth in soft agar required exposure to
100-fold higher concentrations (.1 lM) of these agents than
was required to inhibit colony formation by cells expressing
the EGFR missense mutants or deletion mutant (Figure 4A).
In fact, no signiﬁcant inhibition of anchorage-independent
growth of cells expressing D770_N771insNPG EGFR was
observed at 3 lM geﬁtinib or erlotinib (Figure 4B). The
concentrations of geﬁtinib or erlotinib necessary to reverse
insertion mutant transformation are therefore higher than
the achievable serum concentrations of geﬁtinib (0.5–1.0 lM)
and possibly higher than the achievable serum concentrations
of erlotinib (2.8–4.0 lM) [33,34].
Consistent with this result, all three lung adenocarcinoma
patients with known exon 20 insertion mutants of EGFR have
failed to show a clinical response to treatment and have
instead achieved only stable disease with erlotinib alone (n ¼
1; L. Sequist and T. Lynch, personal communication), or in
combination with chemotherapy (n ¼ 2; D. Eberhard and K.
Hillan, personal communication). These results suggest that
cancers harboring distinct activating kinase domain muta-
tions of EGFR may exhibit a differential sensitivity to speciﬁc
EGFR inhibitors.
Interestingly, the irreversible EGFR inhibitor CL-387,785
[35] is more effective than geﬁtinib or erlotinib for inhibition
of colony formation by cells expressing the exon 20 insertion
mutant (Figure 4C). Calculated IC50 values for geﬁtinib,
erlotinib, and CL-387,785 against D770_N771insNPG were
2.6 lM, 2.5 lM, and 0.2 lM, respectively. CL-387,785 had an
even greater effect on colony formation by cells expressing
L858R EGFR, completely inhibiting transformation at 0.003
lM (unpublished data). These effects are also observed upon
assessment of receptor autophosphorylation (Figure 5).
Although the inhibitory concentrations do not exactly
correlate with the results of the colony formation assay,
probably due to the difference in duration of the assays, the
trends are the same. Insertion mutant autophosphorylation is
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CL-387,785 is more effective than geﬁtinib at inhibiting
insertion mutant (and L858R) autophosphorylation.
Discussion
Treatment with the EGFR inhibitors geﬁtinib and erlotinib
has led to dramatic responses in many lung cancer patients,
predominantly for those cancers in which EGFR mutations
can be detected. However, there has been a subset of lung
cancer patients with these mutations who do not respond to
the EGFR inhibitors in current clinical use.
By demonstrating that lung-cancer derived kinase domain
mutants of EGFR are constitutively activated and that they
can transform cultured mammalian cells, we have provided
an in vitro system with which to study EGFR-dependent
oncogenesis in a genetically homogeneous background.
Although the anchorage-independent growth assay measures
only one of many phenotypes of transformation and does not,
for example, recapitulate tumor microenvironment or
account for the inﬂuence of the immune system on tumor
formation, this system will be useful for dissecting inhibitor
response and downstream signaling pathways, particularly for
those mutants not found in existing cancer-derived cell lines.
Using the NIH-3T3 transformation system, we have
found that transformation by an exon 20 insertion mutant
is resistant to inhibition by geﬁtinib and erlotinib.
Strikingly, transformation by this EGFR exon 20 insertion
mutant is more sensitive to treatment with an irreversible
inhibitor, CL-387,785. This compound was previously
found to be active against EGFR containing the exon 20
point mutation T790M, associated with resistance to
geﬁtinib and erlotinib [19].
These results indicate a need for the use of novel EGFR
inhibitors in primary treatment of lung cancers harboring the
exon 20 insertion mutations. Furthermore, the distinct
inhibitor sensitivity of various EGFR mutants argues that
therapies may need to be targeted against speciﬁc mutant
forms of a protein, whereas generalized inhibition of a
particular oncogenic target may not be sufﬁcient.
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Patient Summary
Background While lung cancer is still one of the deadliest cancers, a new
class of drugs called epidermal growth factor receptor (EGFR) inhibitors
have shown promising results in some patients. As the name suggests,
these drugs inhibit a protein called EGFR, which is altered in a subset of
lung cancers.
What Did the Researchers Do and Find? The aim of this study was to
understand in more detail what role the different EGFR alterations played
in the tumor and which ones made the tumor responsive to EGFR
inhibitor treatment. First, the researchers introduced different altered
EGFR versions into human cells and studied their behavior. The EGFR
protein, which can stimulate cell growth, is normally tightly regulated
and active only when a cell receives a signal from its neighbors.
However, the alterations made the EGFR protein always active,
regardless of a stimulating signal, and caused them to ‘‘grow out of
control.’’ They then treated the cells expressing the various alterations
with different EGFR inhibitor drugs and showed that the specific
alteration determined whether cell growth could be stopped by a
specific drug.
What Do the Results Mean for Patients? EGFR inhibitors are still
considered to be experimental treatment. Researchers are making
progress in understanding how genetic alterations in EGFR cause
abnormal growth in some lung cancers and also which specific
alterations cause the tumor to be responsive to a particular drug. The
goal is to match the tumor and the drug to maximize anti-tumor
response and avoid giving a drug that doesn’t work with a particular
tumor.
Where Can I Get More Information? The following Web sites contain
information on lung cancer, the role of EGFR mutations, and the EGFR
class of drugs.
Lung Cancer Online (follow links for experimental treatments and EGFR
inhibitors):
http://www.lungcanceronline.org/index.htm
US National Cancer Institute information page on lung cancer:
http://www.nci.nih.gov/cancertopics/types/lung
Ongoing clinical trials of EGFR inhibitors:
http://www.clinicaltrials.gov
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